Banner University Medical Center Phoenix: Mesothelioma Care

Banner University Medical Center Phoenix (BUMC Phoenix) is a 770-bed academic medical center located at 1111 E. McDowell Road in Phoenix, Arizona. It serves as the primary teaching hospital for the University of Arizona College of Medicine Phoenix and operates within the Banner Health system, one of the largest nonprofit health systems in the United States. For patients diagnosed with mesothelioma, BUMC Phoenix provides access to a multidisciplinary oncology team capable of managing this rare and aggressive cancer from initial biopsy through surgery, systemic therapy, and survivorship planning.

Mesothelioma is diagnosed in roughly 3,000 Americans each year, according to the American Cancer Society, and its rarity means that most community hospitals see only a handful of cases annually. That scarcity makes specialized academic centers like BUMC Phoenix critically important. The hospital's thoracic surgery and oncology programs are equipped to evaluate candidates for complex procedures such as extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D), surgeries that carry significant risk and demand experienced hands.

Through its affiliation with the University of Arizona Cancer Network, BUMC Phoenix connects patients to resources, tumor board review, and clinical trial access that would otherwise be unavailable in a standard community oncology setting. The University of Arizona Cancer Network holds designation as an affiliate member of the National Cancer Institute (NCI) cancer center network, which means referral pathways to NCI-designated centers are streamlined when a patient's case demands it. According to Banner Health's published program information, the cancer program at BUMC Phoenix is accredited by the American College of Surgeons Commission on Cancer, a credential that requires demonstrated quality benchmarks in multidisciplinary care, cancer registry data collection, and patient navigation services.

If you or a family member has received a mesothelioma diagnosis in Arizona, BUMC Phoenix represents one of the most capable regional options for specialized evaluation, particularly for pleural mesothelioma, which accounts for approximately 80 percent of all mesothelioma cases, per the National Cancer Institute.

BUMC Phoenix's oncology and thoracic surgery teams treat all three primary anatomical forms of mesothelioma. Pleural mesothelioma, which originates in the lining of the lungs, is the most common and the most frequently referred for surgical evaluation. Peritoneal mesothelioma, arising in the abdominal lining, may be evaluated for heated intraperitoneal chemotherapy (HIPEC) in coordination with the hospital's surgical oncology team. Pericardial mesothelioma, involving the heart lining, is exceedingly rare and typically managed with palliative intent given the complexity of surgical access.

Histologically, the hospital's pathology department can distinguish between the three main cell types: epithelioid, sarcomatoid, and biphasic mesothelioma. Cell type matters enormously in treatment planning. Epithelioid tumors respond better to surgery and systemic therapy, while sarcomatoid tumors carry the most guarded prognosis, according to a 2018 analysis published in the Journal of Thoracic Oncology. BUMC Phoenix's tumor board reviews each case with histologic subtype as a central factor in determining the recommended treatment pathway.

Imagine a retired pipe fitter in Tucson who notices he's short of breath climbing stairs. He attributes it to age. Six months later, a chest X-ray reveals a pleural effusion, fluid between the lung and chest wall, and the subsequent biopsy confirms malignant pleural mesothelioma. His story is common. Mesothelioma's symptoms are deceptive precisely because they mimic far more ordinary conditions, and the average time from first symptom to confirmed diagnosis is approximately six months, according to the National Cancer Institute.

The most frequently reported symptoms of pleural mesothelioma include persistent dry or productive cough, shortness of breath (dyspnea), chest pain or tightness, and unexplained fatigue. Pleural effusion, an accumulation of fluid around the lung, occurs in the majority of pleural mesothelioma patients and is often the first abnormality detected on imaging. Peritoneal mesothelioma presents differently, with abdominal swelling, pain, nausea, and unintentional weight loss being the dominant complaints. According to the American Cancer Society, weight loss and fatigue are common across all mesothelioma subtypes as the disease progresses.

At BUMC Phoenix, pulmonology and thoracic surgery teams perform diagnostic thoracentesis (fluid drainage and analysis) as a first step when pleural effusion is present. However, fluid cytology alone is insufficient to confirm mesothelioma in many cases, and tissue biopsy remains the diagnostic gold standard, per guidelines from the National Comprehensive Cancer Network (NCCN).

Asbestos exposure is the primary known cause of mesothelioma, responsible for the vast majority of cases. When asbestos fibers are inhaled or ingested, they can become permanently embedded in the mesothelial tissue lining the lungs, abdomen, or heart. Over a latency period that typically spans 20 to 50 years, these fibers trigger chronic inflammation, DNA damage, and eventually malignant transformation, according to the National Cancer Institute's published overview of mesothelioma etiology.

Arizona's history of mining, construction, shipbuilding support industries, and military installations has left a legacy of occupational asbestos exposure in the region. The state's copper and asbestos mining industries, active through much of the 20th century, exposed workers to significant fiber concentrations. Secondary exposure, where family members of workers were contaminated by fibers brought home on clothing, is also documented in mesothelioma literature. A smaller subset of cases involves exposure to erionite, a naturally occurring mineral fiber found in certain volcanic rock formations, though this is more relevant to specific geographic regions than to urban Phoenix.

Diagnosing mesothelioma accurately requires a sequence of imaging studies, minimally invasive procedures, and pathological analysis that BUMC Phoenix's integrated cancer program is structured to provide. The process typically begins with a chest X-ray or CT scan that reveals pleural thickening, effusion, or a mass. From there, a PET-CT scan is frequently ordered to assess metabolic activity and identify potential lymph node involvement or distant metastasis, per NCCN guidelines for mesothelioma workup.

Tissue biopsy is the definitive diagnostic step. At BUMC Phoenix, thoracic surgeons and interventional pulmonologists perform video-assisted thoracoscopic surgery (VATS) to obtain adequate tissue samples when less invasive approaches yield inconclusive results. The hospital's pathology department uses immunohistochemical (IHC) staining panels, specifically markers such as calretinin, WT-1, and D2-40 for mesothelioma confirmation and differentiation from lung adenocarcinoma, which can appear similar under standard microscopy. According to a 2020 review in Archives of Pathology and Laboratory Medicine, a minimum panel of four IHC markers is recommended for accurate mesothelioma diagnosis.

Once diagnosis is confirmed, staging follows the American Joint Committee on Cancer (AJCC) TNM system. BUMC Phoenix's multidisciplinary tumor board convenes to review staging data and formulate a treatment plan. Patients benefit from the collective expertise of thoracic surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists, all reviewing the same case simultaneously, which is a standard of care that the Commission on Cancer accreditation requires.

Treatment at BUMC Phoenix for mesothelioma follows a multimodal approach, meaning surgery, chemotherapy, radiation, and immunotherapy are considered together rather than in isolation. The specific combination depends on histologic subtype, disease stage, and your overall health and functional status.

Surgical options for eligible patients include pleurectomy/decortication (P/D), which removes the pleural lining while preserving the lung, and extrapleural pneumonectomy (EPP), a more extensive resection that removes the lung, pleura, diaphragm, and pericardium on the affected side. The choice between these procedures is debated in the surgical literature. A 2011 randomized trial known as the MARS trial, published in The Lancet Oncology, raised questions about EPP's survival benefit over non-surgical approaches, and many centers have since shifted toward P/D when surgical resection is pursued. BUMC Phoenix's thoracic surgery team evaluates each candidate individually using pulmonary function testing, cardiac assessment, and performance status criteria.

Systemic therapy has evolved significantly since the FDA approved cisplatin plus pemetrexed (Alimta) as the first-line standard in 2004. In October 2020, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for unresectable pleural mesothelioma based on the CheckMate 743 trial, which demonstrated a median overall survival of 18.1 months compared to 14.1 months with chemotherapy alone, according to data published in The Lancet in 2021. BUMC Phoenix's medical oncology team prescribes both chemotherapy and immunotherapy regimens consistent with current NCCN guidelines.

Radiation therapy, typically intensity-modulated radiation therapy (IMRT), is used as an adjunct to surgery or for palliative symptom control. Palliative care services are integrated into the care team at BUMC Phoenix, addressing pain, breathlessness, and quality of life concerns throughout the treatment course, not only at end of life. This integrated palliative model reflects recommendations from a landmark 2010 New England Journal of Medicine study by Temel et al., which demonstrated that early palliative care integration improved both quality of life and, notably, survival in lung cancer patients.

Mesothelioma carries a serious prognosis. The five-year relative survival rate for all mesothelioma patients in the United States is approximately 10 percent, according to SEER data from the National Cancer Institute. Survival varies substantially by stage and cell type. Patients with early-stage epithelioid mesothelioma who are candidates for aggressive multimodal therapy have reported median survival times exceeding 20 months in specialized center series, while those with sarcomatoid histology or stage IV disease often have median survival under 12 months.

BUMC Phoenix's tumor board approach and access to clinical trials through the University of Arizona Cancer Network may offer eligible patients treatment options beyond standard of care. You should ask your oncologist directly about open trials, since clinical trial participation has historically been associated with access to novel agents before they reach broader availability. The NCI's ClinicalTrials.gov database is the most comprehensive public resource for finding active mesothelioma studies, and BUMC Phoenix's oncology navigation team can assist with identifying eligibility.

Living with a mesothelioma diagnosis involves navigating complex medical decisions, financial pressures, and emotional challenges simultaneously. BUMC Phoenix offers patient navigation services, social work support, and connections to community resources through its Commission on Cancer-accredited program. Navigators can help coordinate appointments across specialties, assist with insurance authorization for high-cost treatments like immunotherapy, and connect you with local support groups.

Because mesothelioma is almost always caused by asbestos exposure, many patients and families are also entitled to pursue legal compensation through asbestos trust funds or litigation. BUMC Phoenix's social work team can provide referrals to patient advocacy organizations, and groups such as the Mesothelioma Applied Research Foundation (MARF) offer financial assistance programs and peer support networks. Documenting your occupational and exposure history in detail is important both for your medical team (it informs risk counseling for family members) and for any legal process you choose to pursue.

Nutritional support, pulmonary rehabilitation, and psychological counseling are all components of comprehensive mesothelioma care that BUMC Phoenix's integrated system can facilitate. Dyspnea management, in particular, is a priority for pleural mesothelioma patients, and palliative pulmonology consultations are available to address breathlessness through both pharmacologic and non-pharmacologic strategies.